Ibrance® (palbociclib) – Expanded indications
April 4, 2019 - The FDA announced the approval of Pfizer’s Ibrance (palbociclib), for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or men; or in combination with Faslodex® (fulvestrant) in patients with disease progression following endocrine therapy.
Top